PHILADELPHIA, PA — Datavault AI (Nasdaq: DVLT) and Wellgistics Health (Nasdaq: WGRX) have signed a binding term sheet to combine a series of healthcare technology, logistics, and consumer health assets into a new entity called DelivMeds AI, a proposed platform the companies value at approximately $4 billion.
The transaction aims to merge pharmacy distribution infrastructure, blockchain-based healthcare data management, biometric verification technology, drone delivery intellectual property, and consumer health products into a single healthcare services business, reflecting growing efforts to integrate artificial intelligence and data-driven tools into pharmaceutical distribution and patient engagement.
The proposed DelivMeds AI structure depends on three concurrent transactions: an expansion of Datavault’s PharmacyChain licensing agreement, the acquisition of QOLPOM biometric health and drone-delivery intellectual property, and the purchase of a controlling interest in Tollo Health.
The companies stated the combined valuation remains subject to an independent fairness opinion, due diligence, financing arrangements, board approvals, and definitive agreements.
A central component of the plan is expanding PharmacyChain, Datavault’s blockchain-enabled platform, to support broader healthcare services applications. The system would connect DelivMeds AI to Wellgistics’ network of more than 6,500 pharmacies and over 200 pharmaceutical manufacturers.
Wellgistics’ EinsteinRx platform would provide prescription processing, eligibility verification, prior authorization, adherence support, and fulfillment services, while PharmacyChain would manage transaction infrastructure through blockchain-based smart contracts.
The companies also plan to acquire the QOLPOM intellectual property portfolio from EOS Technology Holdings and Scilex Holding Company (Nasdaq: SCLX).
According to the companies, the technology includes biometric verification systems designed to confirm patient identity and medication response through wearable devices. The portfolio also includes intellectual property related to drone-based delivery of pharmaceuticals and collection of diagnostic samples.
The third transaction involves acquiring a controlling stake in Tollo Health, which develops medical foods, dietary supplements, telemedicine services, and AI-supported health coaching programs.
Tollo’s portfolio includes products targeting muscle loss associated with GLP-1 weight-loss therapies, long COVID, and acute viral infections.
The companies intend to integrate Tollo’s consumer health platform, Health Lives Here, into the DelivMeds ecosystem. A pilot rollout is targeted for North Carolina in July, with a broader launch planned around activities associated with the August 2026 Pro Football Hall of Fame Game.
As part of the restructuring, Gerald Commissiong has been appointed interim co-chief executive officer of Wellgistics Health.
“There is a tremendous opportunity to transition this highly valuable portfolio of assets into a robust business centered on quantifying and improving patient outcomes using DelivMeds’ unique access to a proprietary healthcare data stack,” Commissiong said.
Datavault Chief Executive Officer Nathaniel Bradley described the initiative as an effort to combine pharmacy delivery infrastructure, logistics technology, and biometric verification capabilities into a direct-to-consumer healthcare platform.
The proposed transaction comes as healthcare companies increasingly pursue AI-driven approaches to prescription fulfillment, remote patient monitoring, digital therapeutics, and consumer engagement. Whether DelivMeds AI can achieve its projected scale will depend on completion of the acquisitions and successful integration of several distinct businesses and technologies.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.